OPRM1 and Respiratory insufficiency due to muscle weakness: However, its utility is limited due to variable pharmacokinetics, including a series of metabolites that are high-efficacy MOR agonists (31, 32), and respiratory depression that cannot be rescued by the standard of care (standard clinical doses of the MOR antagonist naloxone) (33).